期刊
DRUG DISCOVERY TODAY
卷 26, 期 7, 页码 1721-1727出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2021.03.011
关键词
-
资金
- deanship of Scientific Research (DSR) at King Abdulaziz University, Jeddah, Saudi Arabia [FP13542]
Triple-negative breast cancers are a heterogeneous group of breast carcinomas that do not express estrogen receptor, progesterone receptor, and epidermal growth factor receptor 2. Recent trials using immune checkpoint inhibitors for treatment have shown promising early results. This review provides an overview of immunotherapy-based treatments and discusses future opportunities for their use in TNBC.
Triple-negative breast cancers (TNBCs) form a heterogeneous group of breast carcinomas that lack expression of estrogen receptor, progesterone receptor and epidermal growth factor receptor 2. In the past decade, immune checkpoint inhibitors (ICIs) have revolutionized the arena of cancer immunotherapy. Early results are now accumulating from trials involving the treatment of TNBCs with radical ICIs therapies, including combinational therapies that include ICI technologies. In this review, we provide a broad overview of the progress of immunotherapy-based treatments and discuss future opportunities for their use in TNBC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据